These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25182125)

  • 81. Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin.
    Castiñeiras I; Almagro M; Rodríguez-Lozano J; Fernández-Jorge B; Paradela S; Pozo JD; Fonseca E
    J Dermatolog Treat; 2006; 17(6):377-80. PubMed ID: 17853313
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Knowledge translation in healthcare: Incorporating theories of learning and knowledge from the management literature.
    Oborn E; Barrett M; Racko G
    J Health Organ Manag; 2013; 27(4):412-31. PubMed ID: 24003630
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Human Biomolecular Corona of Liposomal Doxorubicin: The Overlooked Factor in Anticancer Drug Delivery.
    Caracciolo G; Palchetti S; Digiacomo L; Chiozzi RZZ; Capriotti AL; Amenitsch H; Tentori PM; Palmieri V; Papi M; Cardarelli F; Pozzi D; Laganà A
    ACS Appl Mater Interfaces; 2018 Jul; 10(27):22951-22962. PubMed ID: 29905462
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
    Joly F; Ray-Coquard I; Fabbro M; Donoghoe M; Boman K; Sugimoto A; Vaughan M; Reinthaller A; Vergote I; Ferrandina G; Dell'Anna T; Huober J; Pujade-Lauraine E
    Gynecol Oncol; 2011 Aug; 122(2):226-32. PubMed ID: 21575983
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Hierarchy of Knowledge Translation: From Health Problems to Ad-Hoc Drug Design.
    Fajardo D; Castano VM
    Curr Med Chem; 2016; 23(26):3000-3012. PubMed ID: 27530406
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
    Sun B; Deng C; Meng F; Zhang J; Zhong Z
    Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models.
    Ito K; Hamamichi S; Asano M; Hori Y; Matsui J; Iwata M; Funahashi Y; Umeda IO; Fujii H
    Cancer Sci; 2016 Jan; 107(1):60-7. PubMed ID: 26509883
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Anticancer Efficacy of the Combination of Berberine and PEGylated Liposomal Doxorubicin in Meth A Sarcoma-Bearing Mice.
    Yahuafai J; Asai T; Oku N; Siripong P
    Biol Pharm Bull; 2018; 41(7):1103-1106. PubMed ID: 29962406
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma.
    Collins Y; Lele S
    J Natl Med Assoc; 2005 Oct; 97(10):1414-6. PubMed ID: 16353663
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Successful Treatment of a Locally Recurrent and Metastatic Malignant Phyllodes Tumor with Accelerated Radiotherapy and Nab-Paclitaxel, Cisplatin, and Liposomal Doxorubicin Chemotherapy.
    Koukourakis IM; Zygogianni A; Kouloulias V; Koukourakis MI
    Chemotherapy; 2021; 66(3):82-86. PubMed ID: 34233328
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
    McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
    BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Liposomes versus metallic nanostructures: differences in the process of knowledge translation in cancer.
    Fajardo-Ortiz D; Duran L; Moreno L; Ochoa H; Castaño VM
    Int J Nanomedicine; 2014; 9():2627-34. PubMed ID: 24920900
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Tackling the reproducibility problem to empower translation of preclinical academic drug discovery: is there an answer?
    Janero DR
    Expert Opin Drug Discov; 2021 Jun; 16(6):595-600. PubMed ID: 33617734
    [No Abstract]   [Full Text] [Related]  

  • 94. A Bibliometric Analysis and Visualization of Current Research Trends in the Treatment of Cervical Spondylotic Myelopathy.
    Yin M; Xu C; Ma J; Ye J; Mo W
    Global Spine J; 2021 Jul; 11(6):988-998. PubMed ID: 32869687
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Mapping the coevolution, leadership and financing of research on viral vectors, RNAi, CRISPR/Cas9 and other genomic editing technologies.
    Fajardo-Ortiz D; Shattuck A; Hornbostel S
    PLoS One; 2020; 15(4):e0227593. PubMed ID: 32294089
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles.
    Parvani JG; Jackson MW
    Endocr Relat Cancer; 2017 Apr; 24(4):R81-R97. PubMed ID: 28148541
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Recent highlights of Chinese medicine for advanced lung cancer.
    He XR; Han SY; Li PP
    Chin J Integr Med; 2017 May; 23(5):323-330. PubMed ID: 28028718
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Hegemonic structure of basic, clinical and patented knowledge on Ebola research: a US army reductionist initiative.
    Fajardo-Ortiz D; Ortega-Sánchez-de-Tagle J; Castaño VM
    J Transl Med; 2015 Apr; 13():124. PubMed ID: 25928238
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Mapping knowledge translation and innovation processes in Cancer Drug Development: the case of liposomal doxorubicin.
    Fajardo-Ortiz D; Duran L; Moreno L; Ochoa H; Castaño VM
    J Transl Med; 2014 Sep; 12():227. PubMed ID: 25182125
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Pegylated liposomal doxorubicin: a guide to its use in various malignancies.
    Lyseng-Williamson KA; Duggan ST; Keating GM
    BioDrugs; 2013 Oct; 27(5):533-40. PubMed ID: 24018470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.